CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
Apatinibdrug
Likely dose
Apatinib 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02878057
NCT02878057Phase 2Completed
CompareCT.gov

Multicenter Phase II Study of Apatinib in Patients With HER-2 Negative Advanced Breast Cancer With Chest Wall Metastasis

Peking University Cancer Hospital & Institute·interventional·Posted Aug 25, 2016·Updated Jan 27, 2021

In Brief

A Phase 2 clinical trial evaluating Apatinib for Breast Cancer. Completed, enrolled 30 participants.

Detailed Summary

The treatment of the patients with recurrent and metastatic breast cancer remains a major problem. There is still a lack of effective targeted therapy for Her-2 negative breast cancer.Based on the present researches on the anti-angiogenesis drugs in advanced breast cancer, the investigators believe that it is necessary to further explore the efficacy and safety of apatinib in advanced breast cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
Countries--
CollaboratorsHebei Medical University Fourth Hospital, Peking University First Hospital, Peking University Third Hospital, Shanxi Province Cancer Hospital

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 25, 2016
Enrollment StartMay 1, 2016
Primary CompletionSep 2, 2020
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 9.9 years ago

Interventions

Apatinibdrug

Dosing regimen: apatinib tablets: 500 mg, Po, QD; 4 weeks as a cycle, continuous treatment until disease progression, death or intolerable toxicity (giving endocrine therapy simultaneously if hormone receptor positive)